|
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. Clinical research trials and Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.. Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis. Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
For Condition: Candidiasis, esophageal,HIV Infections
Status: Completed
Sponsor(s): Janssen Pharmaceutica ,
Synopsis: To evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.
Details:
Eligibility:
Study Type: Interventional, Treatment, Double-Blind, Safety Study
Minimum Age/Maximum Age: 13 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - Esophageal candidiasis. - Histological evidence of Candida spp. at baseline with confirmation by positive mycological culture. - HIV infection or other predisposing risk factor. - Life expectancy of at least 2 months. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Malignancies of the head or neck, if the treatment or disease will interfere with response assessment. - Evidence of systemic fungal infection. - Underlying clinical condition that would preclude study completion. - Judged to be unreliable in regard to following physician's directives. Concurrent Medication: Excluded: - Rifampin. - Rifabutin. - Phenobarbital. - Phenytoin. - Carbamazepine. - Terfenadine. - Astemizole. - H2 blockers. - Continual antacids. - Any investigational drug (expanded access drugs are allowed). Patients with the following prior conditions are excluded: - History of significant hepatic abnormalities or clinical evidence of hepatic disease within 2 months prior to study entry. - History of hypersensitivity to imidazole or azole compounds. Prior Medication: Excluded: - Other orally administered antifungal therapy within 3 days prior to study entry. - Any investigational drug within 1 month prior to study entry (expanded access drugs are allowed).
Total Enrollment:
Location and Contact Information:
Univ Hosps of Cleveland
Cleveland, Ohio, 44106
United States
Dr Eskild A Petersen
Tucson, Arizona, 85724
United States
George Washington Univ Med Ctr
Washington D.C., District of Columbia, 20037
United States
Emory Univ School of Medicine
Atlanta, Georgia, 30303
United States
Austin Infectious Disease Consultants
Austin, Texas, 78705
United States
Univ of North Carolina
Chapel Hill, North Carolina, 27599
United States
Johns Hopkins Univ School of Medicine
Baltimore, Maryland, 21205
United States
Wayne State Univ / Harper Hosp
Detroit, Michigan, 48201
United States
Erie County Med Ctr
Buffalo, New York, 14215
United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, 60612
United States
UCSD Med Ctr
San Diego, California, 92103
United States
Montefiore Med Ctr
Bronx, New York, 10467
United States
Houston Veterans Administration Med Ctr
Houston, Texas, 77030
United States
Dr Douglas Dieterich
New York City, New York, 10016
United States
Infectious Diseases Association / Research Med Ctr
Kansas City, Missouri, 64132
United States
Bowman Gray School of Medicine
Winston Salem, North Carolina, 27157
United States
Los Angeles County - USC Med Ctr
Los Angeles, California, 90033
United States
Univ of Missouri at Kansas City School of Medicine
Kansas City, Missouri, 64108
United States
Additional Information:
Study ID Numbers: 236A; ITR-USA-12
Study Start Date:
Record last reviewed: April 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002132
Other Candidiasis, Esophageal Studies:
1. A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women
2. Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
3. A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients with Weakened Immune Systems
4. A Study of the Side Effects of L-743,872 in Men with Candidal Esophagitis
5. Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
Related Studies:
Other Candidiasis, esophageal Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
|
|
|
|
|
|
|
|